Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Tulsa, OK
NPI: 1356382592Primary Practice Location
Oklahoma Cancer Specialists and Research Institute LLC
12697 E 51st S St, Tulsa, OK
Primary Employer
Oklahoma Cancer Specialists and Research Institute LLC
ocsri.org
HQ Phone
Get M.D. Mark's Phone NumberMobile
Get M.D. Mark's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOK State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 419 | 1,259 |
| 2 | 80053Blood test, comprehensive group of blood chemicals | 386 | 1,216 |
| 3 | 36415Insertion of needle into vein for collection of blood sample | 383 | 1,008 |
| 4 | 83735Magnesium level | 379 | 1,209 |
| 5 | 84100Phosphate level | 379 | 1,209 |
Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Authors: Myo Min, Joseph Mace, Romeo Mandanas, Philip Bonomi
Publication Date: 2013-02-02
Authors: Craig Reynolds, Philip Bonomi, Mark Socinski, Edward Garon, David Spigel
Publication Date: 2014-11-18
Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Authors: Philip Bonomi, Mark Socinski, Edward Garon, David Spigel
Publication Date: 2015-01-23
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Docetaxel, DRUG: Gemcitabine, DRUG: Olaratumab
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Abemaciclib, DRUG: Prednisone, DRUG: Abiraterone acetate
